Forty-two patients diagnosed with relapsed/refractory NSCLC HER2 mutation were treated with an anti-HER2 antibody conjugate called fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu). Here, ERBB2 is linked to non-small cell lung carcinoma.